Jenna Horton
Women's Health · Albany, NYNPI 1689911869
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $24,748 of the $37,089 with a category attached, or 66.7%. AbbVie accounts for 90.8% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2022 at $19,830 and has fallen 88.7% since, to $2,241 in 2025. Among women's health clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 261 payments — averaging $142.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$34K
- Astellas Pharma US Inc$504
- Sumitomo Pharma America, Inc.$476
- Urovant Sciences Inc$344
- Antares Pharma, Inc.$328
- Johnson & Johnson$287
- plus $1K from 21 others
What the payments were for
- Consulting fees$5,05514%
- Speaking & faculty fees$24,74867%
- Travel & lodging$2,7207%
- Food & beverage$4,46812%
- Education$1000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 95 | $33,669 |
| Astellas Pharma US Inc | 30 | $504 |
| Sumitomo Pharma America, Inc. | 17 | $476 |
| Urovant Sciences Inc | 15 | $344 |
| Antares Pharma, Inc. | 23 | $328 |
| Johnson & Johnson | 8 | $287 |
| 180 Medical, Inc. | 12 | $243 |
| Pfizer | 11 | $194 |
| Endo Pharmaceuticals Inc. | 7 | $150 |
| Medtronic | 5 | $115 |
| Merck | 5 | $94 |
| Ferring Pharmaceuticals Inc. | 3 | $93 |
| Tolmar Pharmaceuticals, Inc. | 5 | $83 |
| Hollister Incorporated | 3 | $70 |
| Myovant Sciences Inc. | 3 | $57 |
| Endo USA, Inc. | 2 | $53 |
| Myriad Genetic Laboratories, Inc. | 3 | $50 |
| Blue Earth Diagnostics | 2 | $48 |
| Boston Scientific | 1 | $36 |
| Tolmar, Inc. | 2 | $34 |
| Rochester Medical Corporation | 2 | $32 |
| Urogen Pharma, Inc. | 1 | $26 |
| Mission Pharmacal Company | 2 | $24 |
| Halozyme Inc | 1 | $23 |
| Alnylam Pharmaceuticals Inc. | 1 | $22 |
| Axonics, Inc. | 1 | $18 |
| Dentsply IH AB | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$37,089 in reported general payments places this provider in the 95th percentile of 376 women's health providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 418 | $303,552 |
| GemtesaVibegron | 184 | $174,788 |
| Tamsulosin Hcl | 1,162 | $16,627 |
| Mirabegron ErMirabegron | 23 | $11,693 |
| Tolterodine Tartrate ErTolterodine Tartrate | 52 | $7,288 |
| Oxybutynin Chloride ErOxybutynin Chloride | 194 | $7,018 |
| Dutasteride | 234 | $6,960 |
| Potassium Citrate ErPotassium Citrate | 69 | $6,710 |
| Trimethoprim | 70 | $5,727 |
| Finasteride | 311 | $4,920 |
| Testosterone | 22 | $4,498 |
| Solifenacin Succinate | 67 | $4,257 |
| Silodosin | 50 | $4,220 |
| Methenamine Hippurate | 38 | $3,884 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 33 | $3,859 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $504 | $303,552418 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $476 | $174,788184 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 376 women's health providers in New York.
Other women's health in Albany
- Mollie FinkelAlbany$7K
- Amy SantoroAlbany$3K
- Sophia FrontusBrooklyn$52K
- Austin JacobusNew York$51K
- Stacie WierWilliamsville$12K
- Jenna GoldsmithWilliamsville$9K
- Marjorie Seale-SimpsonMiddletown$6K
- Stacy GarrityNew York$5K
- Sarah WeldNew York$5K
- Kathleen CsillagNew York$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.